Registry of Patients Treated With Systemic Mold-Active Triazoles

What is the purpose of this trial?

The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).

Participation Guidelines

Ages: 6 - 80 years

Gender: Both

Astellas Pharma US, Inc.

Start Date: 10/11/2017

End Date: 12/31/2020

Last Updated: 02/22/2018

Study HIC#: 2000020126REG

Get Involved

For more information about this study, contact:
Ricarda Tomlin
+1 203-785-2073

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image


Maricar Malinis

Principal Investigator